Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer
(2008) In Breast 17(5). p.484-491- Abstract
- We investigate the prognostic significance of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and S-phase fraction (SPF) for distant disease free survival (DDFS) in 219 premenopausal patients with node-negative breast cancer (NNBC). In univariate analysis significantly shorter DDFS was observed for patients with high VEGF (p = 0.006), high uPA (p = 0.001). and high SPF (p < 0.001). The prognostic significance of VEGF varied over time being very, strong for early relapses (0-2.25 years follow-up) (HR = 7.9: p = 0.006) while no difference was seen in the subsequent follow-up period (HR = 1.3: p = 0.62). In a series of bivariate... (More)
- We investigate the prognostic significance of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and S-phase fraction (SPF) for distant disease free survival (DDFS) in 219 premenopausal patients with node-negative breast cancer (NNBC). In univariate analysis significantly shorter DDFS was observed for patients with high VEGF (p = 0.006), high uPA (p = 0.001). and high SPF (p < 0.001). The prognostic significance of VEGF varied over time being very, strong for early relapses (0-2.25 years follow-up) (HR = 7.9: p = 0.006) while no difference was seen in the subsequent follow-up period (HR = 1.3: p = 0.62). In a series of bivariate analyses VEGF provided prognostic information during the whole observation period (0-72 months) in addition to age, tumor size, oestrogen receptor (ER), progesterone receptor (PgR), and uPA. Also this effect was more pronounced during the first follow-up period suggesting VEGF as a marker of early recurrences. (C) 2008 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1283652
- author
- Linderholm, Barbro K. ; Gruvberger, Sofia LU ; Fernö, Mårten LU ; Bendahl, Pär-Ola LU and Malmström, Per LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Early relapses, S-phase fraction (SPF), activator (uPA), Vascular endothelial growth factor (VEGF), Urokinase-type plasminogen, Premenopausal, lymph node-negative breast cancer
- in
- Breast
- volume
- 17
- issue
- 5
- pages
- 484 - 491
- publisher
- Churchill Livingstone
- external identifiers
-
- wos:000260896700009
- scopus:53149153529
- pmid:18508268
- ISSN
- 1532-3080
- DOI
- 10.1016/j.breast.2008.02.010
- language
- English
- LU publication?
- yes
- id
- 09e3c7cc-73e5-4695-842a-47074423b811 (old id 1283652)
- date added to LUP
- 2016-04-01 13:34:31
- date last changed
- 2022-01-27 19:53:06
@article{09e3c7cc-73e5-4695-842a-47074423b811, abstract = {{We investigate the prognostic significance of the pro-angiogenic cytokine vascular endothelial growth factor (VEGF), urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and S-phase fraction (SPF) for distant disease free survival (DDFS) in 219 premenopausal patients with node-negative breast cancer (NNBC). In univariate analysis significantly shorter DDFS was observed for patients with high VEGF (p = 0.006), high uPA (p = 0.001). and high SPF (p < 0.001). The prognostic significance of VEGF varied over time being very, strong for early relapses (0-2.25 years follow-up) (HR = 7.9: p = 0.006) while no difference was seen in the subsequent follow-up period (HR = 1.3: p = 0.62). In a series of bivariate analyses VEGF provided prognostic information during the whole observation period (0-72 months) in addition to age, tumor size, oestrogen receptor (ER), progesterone receptor (PgR), and uPA. Also this effect was more pronounced during the first follow-up period suggesting VEGF as a marker of early recurrences. (C) 2008 Elsevier Ltd. All rights reserved.}}, author = {{Linderholm, Barbro K. and Gruvberger, Sofia and Fernö, Mårten and Bendahl, Pär-Ola and Malmström, Per}}, issn = {{1532-3080}}, keywords = {{Early relapses; S-phase fraction (SPF); activator (uPA); Vascular endothelial growth factor (VEGF); Urokinase-type plasminogen; Premenopausal; lymph node-negative breast cancer}}, language = {{eng}}, number = {{5}}, pages = {{484--491}}, publisher = {{Churchill Livingstone}}, series = {{Breast}}, title = {{Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer}}, url = {{http://dx.doi.org/10.1016/j.breast.2008.02.010}}, doi = {{10.1016/j.breast.2008.02.010}}, volume = {{17}}, year = {{2008}}, }